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Abstract
While new cancer treatments continue to improve patient outcomes, for some cancers there have been limited or no
improvements for a long time. It is for these cases radically new approaches are required. Recent publications proposing ribosome
biogenesis, in particular RNA polymerase I transcription, as a suitable target for cancer treatment has been gaining momentum.
For example, we demonstrated that CX-5461, a specific RNA polymerase I transcription inhibitor, is effective in treating an
aggressive subtype of acute myeloid leukemia, regardless of p53 status. Notably, CX-5461 reduces the leukemia initiating/stem
cells, the cell population believed to be responsible for chemotherapy resistance and disease relapse in numerous cancers.
Targeting ribosome biogenesis, once considered merely a “housekeeping process,” is showing promise in a continuously growing
list of cancers including lymphoma, prostate, and now acute myeloid leukemia. Evidence suggests the therapeutic efficacy of RNA
polymerase I therapy in preclinical models is mediated through a variety of mechanisms including nucleolar stress activation of
p53, DNA damage-like activation of ataxia-telangiectasia mutated/ataxia-telangiectasia and Rad3 related, and cellular differ-
entiation. Overall, the available data suggests the potential for targeting ribosome biogenesis to be effective in a broad spectrum of
cancers. The outcomes of 2 phase 1/2 trials of CX-5461 in hematological malignancies and breast cancer are eagerly awaited.
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Commentary
A growing number of studies have placed ribosome biogenesis
and its cellular location, the nucleolus, into the spotlight as a
novel target for cancer therapy. This is remarkable as, for a
significant period of time, ribosome biogenesis was considered
merely a “housekeeping process” implicated purely in defining
the translational capacity of cells. The recent and ever increas-
ing body of work, primarily the result of the “omics” era, is
collectively placing the regulation of ribosome biogenesis and
the nucleolus as an essential hub for cellular homeostasis and
whose dysregulation has broad consequences for the cell.
Indeed, there are now studies demonstrating that dysregulation
of ribosome biogenesis in diseases, such as cancer and riboso-
mopathies, impacts on the nucleolus to control the activity of
tumor suppressors, oncogenes, global genome stability, and
cell fate decisions.1-4
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The first step in the synthesis of new ribosomes is the
transcription of the ribosomal RNA genes (rRNA) by RNA
polymerase I (Pol I). This process is highly upregulated in
many malignant cells compared to their nonmalignant counter-
parts through the action of oncogenes such as MYC and the
release from inhibition by tumor suppressors such as the reti-
noblastoma protein or p53. Intriguingly, although it remained
unrecognized for many years, it appears that many highly
effective chemotherapeutics for cancer strongly perturb ribo-
some biogenesis at the step of rDNA transcription and/or ribo-
somal RNA processing; examples include platinum-based
chemotherapeutics such as Oxaliplatin or Cisplatin and anti-
metabolites such as 5-Fluorouracil.5 This suggests that at least
part of their efficacy might be mediated through inhibition of
ribosome biogenesis rather than the traditional view that their
cytotoxicity is mediated solely by damaging DNA. Although
these chemotherapeutic drugs in many cases significantly
reduced disease burden and prolonged patient survival, their
major drawback is the severe toxicity caused by their conco-
mitant ability to induce genome-wide DNA damage in sur-
rounding normal tissue. In the longer term, this frequently
results in the development of secondary neoplasms such as
therapy-related acute myeloid leukemia (AML) and myelo-
dysplasia. For example, the incidence rate after conventional
therapy to develop these secondary malignancies ranges
between 0.8% and 6.3%.6 These observations led to the
development of small molecules that selectively inhibit
Pol I transcription including CX-5461 (Senhwa Biosciences,
San Diego, CA) to target malignancies with reduced toxicity
and improve efficacy compared to conventional chemothera-
pies that target multiple processes.7,8
One cancer whose core cytotoxic therapy has not substan-
tially changed over the last 30 years is AML. In 2016 alone,
19 950 new AML cases and 10 430 disease-related deaths were
reported in the United States.9 Acute myeloid leukemia is a
disease of the elderly with an incidence of 1.3 annual cases per
100 000 under the age of 65 years increasing to 12.2 cases per
100 000 in individuals over the age of 65 years. The 5-year
survival rate for patients with de novo AML lies around
27%.9,10 Therapy-related AML, however, has a more unfavor-
able prognosis due to the accumulation of mutations such as
those in the tumor suppressor p53 induced through chemother-
apy and/or radiation.
These statistics reveal the urgent need for the development
of new efficacious therapies preferentially without severe side
effects. A promising novel therapeutic agent falling in this
category is the selective Pol I transcription inhibitor
CX-5461. We tested CX-5461 on a particularly aggressive sub-
type of AML, mixed-lineage leukemia (MLL)–driven AML,
which fails to response to standard of care treatment. Our
studies found that maximum-tolerated doses of CX-5461 out-
performed standard of care therapy (cytarabine/doxorubicin) in
2 different murine models of MLL-AML.4 Remarkably, in this
study, the therapeutic response differed from that observed in
B-cell lymphoma where CX-5461 mediated its response in a
p53-dependent manner. CX-5461 therapy significantly
prolonged overall survival in both p53 wild-type and p53 null
AML. The finding that CX-5461 treats p53 null AML has
significant clinical relevance as the frequency of p53 mutation
increases over the course of conventional chemotherapies
treatment and at disease relapse. CX-5461 not only treated
syngeneic models of murine AML but also significantly
reduced tumor burden in patient-derived xenograft of primary
human AML (Figure 1). These studies suggest that pharmaco-
logical inhibition of Pol I transcription could be utilized as a
novel therapy option for patients with refractory AML.
Intriguingly, inhibition of Pol I transcription induces a
heterogeneous AML tumor cell response. Induction of p53-
dependent apoptosis and defects in G1/S transition were
observed, as well as, the activation of a p53-independent
DNA damage-like response mediated via ATM/ATR activa-
tion altering G2/M cell cycle progression and induction of
differentiation1,4 (Figure 2). Our study demonstrated that
CX-5461 p53-independent activation of ATM/ATR signaling
occurred in the absence of global DNA damage. Mechanis-
tically, we showed that CX-5461 induces an unusual chro-
matin structure in which transcriptionally competent relaxed
rDNA repeats are devoid of transcribing Pol I, leading to non-
canonical activation of ATM signaling selectively within the
rDNA in the nucleoli. Since CX-5461 does not induce global
DNA damage, the risk of the development of secondary
therapy–related cancers would be reduced compared to other
chemotherapy treatments, for example, cytarabine and
anthracycline-based regimes that cause the genome-wide accu-
mulation of DNA damage.
In addition to apoptosis and cell cycle defects, Pol I inhibi-
tion by CX-5461 triggered myeloid differentiation in leukemic
blasts in vivo which is likely to contribute to the drug’s ther-
apeutic efficacy. This observation is consistent with an increas-
ing number of studies describing a direct link between the rate
of Pol I transcription/ribosome biogenesis and differentiation.
In particular, it appears that ongoing Pol I transcription is
important for stem cell maintenance, and its downregulation
is associated with the loss of stemness and induction of
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Figure 1. CX-5461 has significant therapeutic potential in primary
human AML. CX-5461 therapy (6 doses, 40 mg/kg) reduces the
number of primary human CD45þ cells in the bone marrow of
engrafted NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz) mice (***P ¼
.0006; n¼ 7). Graph represents mean (SD). Unpaired 2-tailed Student
t test. AML indicates acute myeloid leukemia.
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differentiation in the stem/progenitor cells.2,11,12 Interestingly,
recent research demonstrated that the abundance of a number
of Pol I-specific transcription factors, including UBFT and
SL-1, decreases upon differentiation that correlates with
downregulation of Pol I transcription.13 On the other hand,
downregulation of Pol I transcription by targeted knockdown
of another Pol I-specific transcription factor RRN3 Transcrip-
tion initiation factor-1A induces myeloid differentiation in
human AML cell lines and mouse hematopoietic stem cells.11
Other evidence supporting a role of Pol I transcription in stem-
ness comes from the discovery that numerous factors involved
in ribosome biogenesis are enriched in stem/progenitor cells;
for example, TAF1B, TCOF1, and fibrillarin and a number of
the “canonical” pluripotency factors such as Oct3-4/POU5F1,
Sox2, Nanog, and KLF4 directly associated with the rDNA in
mouse embryonic stem cells.14
Our observation that Pol I transcription regulates stem cell
maintenance and differentiation has significant implications for
the clinic. Specifically, inhibition of Pol I transcription reduced
the clonogenic potential of malignant cells and most impor-
tantly reduced the frequency of leukemia initiating/stem cell
(LIC). The LIC is the cell population believed to be responsible
for chemotherapy resistance and disease relapse in numerous
cancers. Many chemotherapies ultimately fail because while
they reduce the bulk of the tumor they do not eradicate the
LIC. A drug’s ability to target LICs will have a profound
impact on clinical efficacy and is absolutely essential in achiev-
ing long-term remission and disease-free survival. This is not
only relevant to leukemia but also a growing number of can-
cers, that is, breast and colorectal cancers are postulated to have
a cancer initiating/stem cell population.
In conclusion, our work demonstrates that CX-5461 treats
aggressive hematologic malignancies. Most strikingly, we
show that targeting rDNA transcription effectively prolongs
survival by reducing the leukemia-initiating potential and
suppresses the clonogenic capacity of the LICs population in
primary human and murine models of AML.
Cumulatively, these findings and favorable toxicology
studies have led to the initiation of 2 clinical trials, a phase I
in Australia for patients with advanced hematologic malignan-
cies (Australian New Zealand Clinical Trials Registry,
#12613001061729) and a phase I/II in Canada (NCT02719977)
for the treatment of solid tumors.
Finally, we note that despite CX-5461 providing significant
improvements in the therapeutic window in our cancer models
compared to conventional therapies, the disease often relapses.
Thus, future studies must focus on the development of effective
combination therapies. So far, promising results have been
achieved by dual inhibition of Pol I transcription and
ribosome function in B-cell lymphoma15 and models of prostate
cancer.16 It is important to note that we are developing second-
generation Pol I inhibitors focusing on improving its drug like
qualities and penetrance of the blood–brain barrier to open up
new treatment options for patients with metastatic disease.
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Figure 2. Inhibition of RNA polymerase I transcription activates p53-
dependent and independent pathways. Schematic overview of down-
stream signaling pathways activated by pharmacological inhibition of
Pol I transcription. CX-5461 inhibits Pol I transcription at the stage of
initiation activating 2 main pathways: a canonical nucleolar stress
response leading to accumulation of p53 and a DNA damage-like
response activating ATM/ATR signaling. Both pathways induce dif-
ferent cellular responses including apoptosis, G1/S, and G2/M cell
cycle defects and/or differentiation. ATM indicates ataxia-
telangiectasia mutated; ATR, ataxia-telangiectasia and Rad3 related;
CDK, cyclin-dependent kinases; CHK, checkpoint kinases; HDM2,
human double minute 2; Pol I, RNA polymerase I; rDNA, ribosomal
DNA; SL-1, selectivity factor 1; TBP, TATA-binding protein; UBFT,
upstream binding factor; UCE, upstream control element.
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